Acute ischaemic strokes occur despite the use of direct oral anticoagulants (DOACs). Evidence-based scale is necessary to assess ischemic stroke risk in atrial fibrillation (AF) patients.
Inclusion Criteria:
Exclusion Criteria:
Consecutive inclusion of patients undergoing DOAC therapy
Consecutive inclusion of patients with AF who experience ischemic stroke despite direct oral anticoagulant DOACs.
Barcelona, Barcelona, Spain
jjuegam.germanstrias@gencat.cat934651200
Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)
Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs Warfarin)
An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers
An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres
The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)
DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation
DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial
Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation